Safety Lead-In of the MEK Inhibitor Trametinib in Combination with GSK2141795, an AKT Inhibitor, in Patients with Recurrent Endometrial Cancer: An NRG Oncology/GOG Study

OBJECTIVE: We sought to determine safety and efficacy of the AKT inhibitor, GSK2141795, combined with the MEK inhibitor, trametinib, in endometrial cancer. METHODS: Patients with measurable recurrent endometrial cancer were eligible. One to two prior cytotoxic regimens were allowed; prior use of a M...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Gynecol Oncol
Main Authors: Westin, Shannon N., Sill, Michael W., Coleman, Robert L., Waggoner, Steven, Moore, Kathleen N., Mathews, Cara A., Martin, Lainie P., Modesitt, Susan C., Lee, Sanghoon, Ju, Zhenlin, Mills, Gordon B., Schilder, Russell J., Fracasso, Paula M., Birrer, Michael J., Aghajanian, Carol
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6922584/
https://ncbi.nlm.nih.gov/pubmed/31623857
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2019.09.024
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados